Our Pricing

What Results Can You Expect From Mounjaro Treatment?

Published on: June 03, 2026

Understanding mounjaro results uk real patients can achieve helps set realistic expectations for your weight loss journey. At Cured Pharmacy, we provide genuine UK-licensed Mounjaro (tirzepatide) from £124.99 with transparent clinical guidance on the outcomes you may experience based on robust trial data and real-world evidence.

Clinical Trial Results: What the Evidence Shows

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. In the landmark SURMOUNT-1 trial involving 2,539 adults with obesity, participants achieved substantial weight reduction across all dose levels over 72 weeks [1].

Those receiving the 15mg maintenance dose — the highest licensed strength — experienced an average body weight reduction of 22.5% from baseline [1]. The 10mg dose produced average reductions of 21.1%, whilst the 5mg dose achieved 15.0% average weight loss [1]. These results significantly exceeded the placebo group, which lost an average of 3.1% body weight [1].

Importantly, 91% of participants on the 15mg dose achieved at least 5% weight loss, 83% achieved at least 10% reduction, and 57% lost 20% or more of their starting body weight [1]. These outcomes represent some of the most substantial weight reductions observed in clinical trials for any licensed obesity medication in the UK.

Mounjaro Results Timeline: When Will You Notice Changes?

Weight loss with Mounjaro follows a gradual escalation pattern as your dose increases over the first 20 weeks of treatment. Most patients begin noticing appetite suppression within the first 1-2 weeks, though measurable weight changes typically emerge by weeks 4-8 [2].

The treatment protocol starts at 2.5mg weekly for four weeks, then increases to 5mg for another four weeks. Your UK prescriber may continue escalating your dose every four weeks — to 7.5mg, 10mg, 12.5mg, and finally 15mg — based on your tolerance and response [2]. Maximum weight loss effects are generally observed between weeks 36-72 of continuous treatment [1].

In clinical trials, the median time to achieve 5% weight loss was approximately 12 weeks for those on higher maintenance doses [1]. However, individual results vary considerably based on adherence, lifestyle modifications, starting BMI, and metabolic factors. Your prescriber will monitor your progress and adjust treatment accordingly.

Factors That Influence Your Results

Several variables affect how much weight you may lose on Mounjaro. Patients who combine treatment with structured dietary changes and regular physical activity typically achieve superior outcomes compared to medication alone [3]. Your starting BMI also plays a role — those with higher initial body weight often see greater absolute weight reduction, though percentage losses remain consistent across BMI categories [1].

Adherence to the weekly injection schedule is crucial. Missing doses or inconsistent administration can reduce treatment efficacy and delay results. Additionally, certain medications and medical conditions may influence how your body responds to tirzepatide, which is why comprehensive prescriber assessment before starting treatment is essential.

Comparing Mounjaro Results to Other Weight Loss Treatments

When evaluating mounjaro results uk data against alternative treatments, tirzepatide consistently demonstrates superior weight reduction outcomes. In head-to-head comparisons, Mounjaro produced significantly greater weight loss than semaglutide 1mg (the GLP-1 agonist used in Wegovy) at comparable timepoints [4].

The SURPASS-2 trial directly compared tirzepatide against semaglutide in adults with type 2 diabetes. Participants on tirzepatide 15mg lost an average of 13.4kg compared to 8.0kg in the semaglutide 1mg group over 40 weeks — a difference of 5.4kg favouring tirzepatide [4]. This advantage stems from tirzepatide's dual receptor mechanism, activating both GIP and GLP-1 pathways rather than GLP-1 alone.

Older weight loss medications like orlistat (Xenical) typically produce more modest results, with average weight reductions of 3-5% when combined with dietary modification [5]. Liraglutide (Saxenda), a daily GLP-1 injection, achieves average weight loss of approximately 8% over 56 weeks [6]. Mounjaro's superior efficacy makes it a preferred option for patients requiring substantial weight reduction, subject to prescriber assessment and suitability.

Managing Side Effects While Achieving Results

Gastrointestinal side effects are the most commonly reported adverse events with Mounjaro, particularly during dose escalation phases. In clinical trials, nausea occurred in 29-33% of participants, diarrhoea in 21-23%, and vomiting in 10-12%, with most cases being mild to moderate in severity [1].

These symptoms typically diminish as your body adjusts to each new dose level. Starting at the lowest 2.5mg dose and gradually escalating helps minimise side effects whilst building tolerance. Your UK prescriber may recommend slower titration if you experience persistent gastrointestinal symptoms, or suggest symptomatic management strategies such as eating smaller meals and avoiding high-fat foods.

More serious but rare adverse events include pancreatitis, gallbladder problems, and allergic reactions. Mounjaro carries a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though relevance to humans remains unclear [2]. Your prescriber will review your complete medical history and contraindications before prescribing, and you should report any severe or persistent symptoms immediately.

Optimising Treatment Tolerance

Simple adjustments can improve your experience on Mounjaro whilst maintaining treatment efficacy. Injecting at consistent times each week, staying well-hydrated, and eating slowly can reduce nausea. Some patients find taking the injection in the evening minimises daytime symptoms, though you can administer Mounjaro at any time regardless of meals [2].

If side effects become intolerable at a particular dose, your prescriber may maintain you at the previous lower dose rather than continuing escalation. Clinical trials showed that even the 5mg and 10mg maintenance doses produce clinically meaningful weight loss, so remaining at a tolerable dose is preferable to discontinuing treatment entirely [1].

Maintaining Weight Loss After Stopping Mounjaro

Long-term weight maintenance after discontinuing Mounjaro presents a significant challenge, as appetite-regulating effects diminish once treatment stops. In withdrawal studies, participants regained approximately two-thirds of their lost weight within one year of stopping tirzepatide, though they still maintained some benefit compared to baseline [7].

This pattern reflects the chronic nature of obesity as a medical condition rather than a treatment failure. Mounjaro addresses the physiological mechanisms driving excess weight — reduced satiety signalling and elevated appetite — but these underlying factors resurface when medication is withdrawn. Many patients require ongoing treatment to sustain their weight loss results, similar to how other chronic conditions like hypertension require continuous management.

If you plan to stop Mounjaro, working with your prescriber to develop a structured maintenance plan is essential. This typically includes continued dietary modification, regular physical activity, behavioural strategies, and potentially transitioning to alternative weight management approaches. Some patients may benefit from intermittent or lower-dose maintenance therapy rather than complete cessation, though this approach requires individualised prescriber guidance.

Accessing Mounjaro Results UK Through Cured Pharmacy

At Cured Pharmacy, we provide transparent access to genuine UK-licensed Mounjaro from £124.99 with all prescriptions issued following comprehensive clinical assessment by our UK-registered prescribers. Our online consultation takes under three minutes and covers your medical history, current medications, weight loss goals, and suitability for tirzepatide therapy.

Your treatment plan will be personalised based on your individual circumstances, with clear guidance on dose escalation, injection technique, managing side effects, and monitoring your progress. We dispense only MHRA-approved medications sourced through licensed UK wholesalers, ensuring you receive authentic Mounjaro KwikPens with full product traceability.

Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees all clinical services and ensures compliance with GPhC standards and UK pharmaceutical regulations. We offer discreet packaging and convenient delivery options, with ongoing prescriber support throughout your treatment journey. All consultations and prescriptions are provided by UK-registered healthcare professionals in accordance with MHRA and GPhC guidelines.

Starting Your Mounjaro Treatment

Beginning treatment is straightforward. Complete our free online consultation, which will be reviewed by a UK prescriber who will assess your suitability for Mounjaro based on your BMI, medical history, previous weight loss attempts, and any contraindications. If approved, your prescription will be dispensed by our GPhC-registered pharmacy and dispatched in discreet packaging.

Your first prescription will include the 2.5mg starter dose with clear instructions on injection technique, storage, and dose escalation schedule. Follow-up consultations ensure your treatment remains appropriate and effective as you progress through higher doses. Remember that all prescription medications require ongoing prescriber oversight, and you should never source Mounjaro from unlicensed suppliers or without proper medical supervision.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–218. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Retrieved from https://www.medicines.org.uk/emc/product/14441 [accessed 13 August 2026]
3. Wadden, T. A., Bailey, T. S., Billings, L. K., et al. (2021). Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA, 325(14), 1403–1413. https://doi.org/10.1001/jama.2021.1831 [accessed 13 August 2026]
4. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
5. Yanovski, S. Z., & Yanovski, J. A. (2014). Long-term Drug Treatment for Obesity: A Systematic and Clinical Review. JAMA, 311(1), 74–86. https://doi.org/10.1001/jama.2013.281361 [accessed 13 August 2026]
6. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
7. Wilding, J. P. H., Batterham, R. L., Davies, M., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725 [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on numerous factors including adherence, lifestyle modifications, and individual metabolic response. Mounjaro is a prescription-only medicine licensed by the MHRA for weight management in adults with a BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities, alongside a reduced-calorie diet and increased physical activity.